Unicycive Therapeutics's market cap is currently $63.31M. The company's EPS TTM is $-0.796; its P/E ratio is ―; Unicycive Therapeutics is scheduled to report earnings on March 27, 2025, and the estimated EPS forecast is $-0.09. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Income Statement
Total Revenue	$ 675.00K	$ 951.00K	$ 0.00	$ 0.00	$ 0.00
Gross Profit	$ 675.00K	$ 944.00K	$ -1.00K	$ 0.00	$ 0.00
Operating Income	$ -20.77M	$ -18.05M	$ -8.98M	$ -2.02M	$ -1.96M
EBITDA	$ -30.18M	$ -18.05M	$ -8.98M	$ 0.00	$ -63.00K
Net Income	$ -30.54M	$ -18.06M	$ -10.63M	$ -2.51M	$ -2.30M
Balance Sheet
Cash & Short-Term Investments	$ 9.70M	$ 455.00K	$ 16.58M	$ 0.00	$ 15.00K
Total Assets	$ 14.19M	$ 2.82M	$ 18.74M	$ 204.00K	$ 19.00K
Total Debt	$ 811.00K	$ 155.00K	$ 306.00K	$ 2.51M	$ 460.00K
Net Debt	$ -8.89M	$ -300.00K	$ -16.27M	$ 2.51M	$ 445.00K
Total Liabilities	$ 18.00M	$ 3.28M	$ 2.26M	$ 2.88M	$ 903.00K
Stockholders' Equity	$ -3.81M	$ -466.00K	$ 16.48M	$ -2.67M	$ -884.00K
Cash Flow
Free Cash Flow	$ -18.30M	$ -15.65M	$ -5.80M	$ -1.46M	$ -1.18M
Operating Cash Flow	$ -18.28M	$ -15.65M	$ -5.77M	$ -1.46M	$ -1.18M
Investing Cash Flow	$ -12.00K	$ -2.00K	$ -29.00K	$ 0.00	$ 0.00
Financing Cash Flow	$ 27.54M	$ -471.00K	$ 22.38M	$ 1.44M	$ 1.17M

Currency in USD

Unicycive Therapeutics Earnings and Revenue History

Income Statement >

Unicycive Therapeutics Debt to Assets

Balance Sheet >

Unicycive Therapeutics Cash Flow

Cash Flow >

Unicycive Therapeutics Forecast EPS vs Actual EPS

Earnings >

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing